M 043
Alternative Names: AAV-NAGLU-S1S3; Lenti-NAGLU-S1S3; M-043; Sanfilippo B (MPSIIIB)Latest Information Update: 09 Feb 2023
Price :
$50 *
At a glance
- Originator M6P Therapeutics
- Class Gene therapies
- Mechanism of Action Alpha N acetyl D glucosaminidase replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Mucopolysaccharidosis III
Most Recent Events
- 09 Feb 2023 M 043 receives Rare pediatric drug for Enzyme replacement therapy status for in USA prior to February 2023 (M6P Therapeutics website, February 2023)
- 04 Feb 2021 M 043 is available for licensing as of 03 Feb 2021
- 03 Feb 2021 Preclinical trials in Mucopolysaccharidosis III in USA (Parenteral) (M6P Therapeutics pipeline, February 2021)